ReviewFrontiers in aging neuroscience2024
The neural basis of neuropsychiatric symptoms in Alzheimer's disease.
Review in Frontiers in aging neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Animal-Assisted Therapy in Dementia: A Systematic Review and Meta-Analysis of Cognitive, Affective, and Behavioral Outcomes.Journal of clinical medicine · 2026Review
- Considerations for the selection and phenotyping of mouse models for the study of Alzheimer's disease.STAR protocols · 2026Review
- Prescription cascades associated with acetylcholinesterase inhibitors use: a high-throughput sequence symmetry analysis.Age and ageing · 2026Article
- The emergence of neuropsychiatric symptoms in preclinical Alzheimer's disease: An emotion regulation perspective.Neuron · 2026Review
- Article
- Investigating the Impact of ABCB1 3435C>T (rs1045642) Variant on Severity and Cognitive Decline in Egyptian Alzheimer's Disease Patients.Molecular neurobiology · 2026Article
- Neurotransmitter Systems in Alzheimer's Disease.Current issues in molecular biology · 2026Review
- Distinct Regulatory Genomic Architectures Distinguish Early-Onset from Late-Onset Alzheimer's Disease.Genes · 2026Article
- Structural and functional brain alterations in depression with Alzheimer's disease and mild cognitive impairment: a multimodal coordinate-based meta-analysis.Frontiers in aging neuroscience · 2026Review
- The role of the anterior cingulate cortex in anxiety control, from circuits to disorders.Frontiers in psychiatry · 2026Review
- Sex hormones in the nucleus incertus: a novel perspective on sex/gender differences in memory and mood dysfunction in Alzheimer's disease.Frontiers in aging neuroscience · 2026Review
- Challenges and Social Implications of Informal Caregiving for People with Alzheimer's: A Qualitative Study.Healthcare (Basel, Switzerland) · 2025Article
- Uncovering the Role of Neuropsychiatric Symptoms in Cognitive Impairment Progression.Proceedings. IEEE International Conference on Bioinformatics and Biomedicine · 2025Article
- Review
- Integration of Neuroimaging and Molecular Biomarkers in the Diagnosis of Alzheimer's Disease and Frontotemporal Dementia: The Promise of fMRI.Current Alzheimer research · 2025Review
- Neuropsychiatric symptoms in mild cognitive impairment and early Alzheimer's disease: Clinical pattern and diagnostic implications.AIMS neuroscience · 2025Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Neuropsychiatric symptoms (NPS) such as depression, anxiety, apathy and aggression affect up to 90% of Alzheimer's disease (AD) patients. These symptoms significantly increase caregiver stress and institutionalization rates, and more importantly they are correlated with faster cognitive decline. However, the neuronal basis of NPS in AD remains largely unknown. Here, we review current understanding of NPS and related pathology in studies of AD patients and AD mouse models. Clinical studies indicate that NPS prevalence and severity vary across different AD stages and types. Neuroimaging and postmortem studies have suggested that pathological changes in the anterior cingulate cortex, hippocampus, prefrontal cortex, and amygdala are linked to NPS, although the precise mechanisms remain unclear. Studies of AD mouse models have indicated that amyloid-beta and tau-related neurodegeneration in the hippocampus, prefrontal cortex, and anterior cingulate cortex are correlated with NPS-like behavioral deficits. A better understanding of the NPS phenotypes and related pathological changes will pave the way for developing a better management strategy for NPS in AD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.